Travere Therapeutics Files 8-K on Financial Condition

TL;DR

**Travere Therapeutics just dropped an 8-K about its financials, watch for details!**

AI Summary

Travere Therapeutics, Inc. filed an 8-K on January 8, 2024, to report an event related to its results of operations and financial condition. This filing, under SEC File Number 001-36257, indicates that the company is providing an update on its financial performance. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock price (TVTX) depending on whether the news is positive or negative.

Why It Matters

This filing signals that Travere Therapeutics is disclosing new financial information, which could influence investor perception and the stock's valuation.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying financial information it refers to could carry significant risk or opportunity.

Analyst Insight

A smart investor would look for the specific financial details that this 8-K refers to, as the filing itself is merely a notification of an event related to financial condition, not the full disclosure.

Key Players & Entities

• Travere Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• 001-36257 (string) — Commission File Number for Travere Therapeutics
• TVTX (string) — trading symbol for Travere Therapeutics Common Stock
• The Nasdaq Global Market (string) — exchange where Travere Therapeutics Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share TVTX The Nasdaq Global Ma

Filing Documents

• d87492d8k.htm (8-K) — 24KB
• d87492dex991.htm (EX-99.1) — 35KB
• g87492g0105181214025.jpg (GRAPHIC) — 3KB
• 0001193125-24-003866.txt ( ) — 193KB
• tvtx-20240108.xsd (EX-101.SCH) — 3KB
• tvtx-20240108_lab.xml (EX-101.LAB) — 18KB
• tvtx-20240108_pre.xml (EX-101.PRE) — 11KB
• d87492d8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Travere Therapeutics, Inc. (the "Company") issued a press release announcing certain preliminary financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Travere Therapeutics, Inc. dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRAVERE THERAPEUTICS, INC. Dated: January 8, 2024 By: /s/ Elizabeth E. Reed Name: Elizabeth E. Reed Title: Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR